Phase 4 N=19 Use of Cidofovir for Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Change in Papilloma Severity — 13.2; 12; 3.7; 3.6 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=45 The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder
Premenstrual Dysphoric Disorder · Premenstrual Syndrome
Primary: Change in Cortical Gama-aminobutyric Acid Levels (GABA Levels) Pre and Post SSRI Treatment
Phase 4 N=489 Prospective Sexual Function Study for BPH Subjects
Prostatic Hyperplasia
Primary: Changes From Baseline (BL) in Total Score From the Full Men's Sexual Health Questionnaire (MSHQ) at 12 Months — -0.7; -8.7 Scores on a scale — p=<0.001
Phase 4 N=39 EXPAREL® for Pain After Tonsillectomy
Tonsillectomy · Tonsillitis · Post-operative Pain
Primary: Pain Score (Pain Scores on a 0/10 Scale) — 3.07; 4.9; 1.76; 1.42 units on a scale — p=0.043
Phase 4 N=3,080 A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
Rheumatoid Arthritis
Primary: Time to First Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event — NA; NA Months
Phase 4 N=96 Hepatic Xenetix-CT Perfusion
Hepatocellular Carcinoma
Primary: Blood Volume (BV) According to Degree of Lesions Differentiation — 15.930; 13.958 mL/100 grams
Phase 4 N=600 Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia
HCV HIV
Primary: Number of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 516 Participants
Phase 4 N=183 Spinal Anesthesia With Hyperbaric Levobupivacaine 0.75% for Ambulatory Knee Arthroscopy
Disorder of Knee · Anesthesia
Primary: Probability of Motor Block — 5; 20; 27 percentage of motor block
Phase 4 N=93 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device
Multiple Sclerosis · Relapsing-Remitting
Primary: Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Psychological Score at Month 12 — 35.19; 30.48; -2.44; -3.04 units on a scale — p=0.9148
Phase 4 N=69 ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study.
Venous Reflux
Primary: Pain — 0.7; 1.9 units on a scale — p=<0.0001
Phase 4 N=25 VANOS Cream and Skin Barrier Function
Atopic Dermatitis
Primary: Change in Eczema Severity and Area Index — 6.01 units — p=<0.01
Phase 4 N=12 Trial of Aripiprazole in the Treatment of CD in Adolescents
Conduct Disorder
Primary: The Primary Outcome Efficacy Measure: Rating of Aggression Against People and/or Property Scale (RAAPP) (Kemph et al 1993) — 1.7 units on a scale
Phase 4 N=549 Study of Long-term Peg Intron vs. Colchicine in Non-responders.
Hepatitis C Virus · Advanced Fibrosis · Cirrhosis
Primary: Determination of the Effect of PEG-Intron 0.5mg Per kg Weekly sc Versus Colchicine 0.6mg Bid Daily on: — 53; 59 Participants
Phase 4 N=40 Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride
Type 2 Diabetes · Hypoglycemia
Primary: Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE) — 6.68; 6.23 mg/dL — p=0.4510
Phase 4 N=24 Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) at 12 Weeks — 1.76; 1.86 Liters — p=0.262